November 2, 2023 — The second round of late-breaking clinical trials results from the Vascular InterVentional Advances Conference, VIVA23, have been announced, with results from three trial outcomes presented in the Oct. 31 afternoon session.

October 31, 2023 — Results of four late-breaking clinical trials presented during the The VEINS Conference 2023, taking place Oct. 28-30 in Las Vegas, NV have been announced in a summary news release by The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research.

October 31, 2023 — Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair (

October 31, 2023 — SMT (Sahajanand Medical Technologies), a leading medical device company in India, focused on innovative patient care in cardiovascular segment, today announced positive results of its recent clinical trial 

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that the U.S. Food and Drug Administration (FDA) has provided clearance of the company’s Investigational New Drug (IND) application to initiate clinical testing of TN-401. 

October 30, 2023 — Shockwave Medical, Inc., which develops technologies for the treatment of cardiovascular disease, has announced the planned United States introduction of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter, following approval by the U.S. Food and Drug Administration. The enhanced C2+ catheter made its U.S.

October 30, 2023 — Boston Scientific Corporation on Friday announced positive 12-month results from the pivotal AGENT IDE clinical trial of the 

October 30, 2023 — Abbott announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK) in people with chronic limb-threatening ischemia (CLTI). CLTI is a severe stage of peripheral artery disease (PAD) due to advanced arterial blockage in the lower extremities.

October 30, 2023 — -egnite, Inc., a leading cardiovascular digital health company, announced today that novel research on aortic stenosis (AS) was presented by cardiologist Philippe Généreux, MD, Director of the Struct

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now